Clinical review report. (Ipsen Biopharmaceuticals Canada, Inc.). AbobotulinumtoxinA (Dysport therapeutic) :
The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the treatment of upper limb spasticity (ULS) in adults.
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534668/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Edition: | Version 1.0. |
| Series: | Common drug review clinical review report.
|
| Subjects: |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | p2436564 | ||
| 005 | 20240212122436.0 | ||
| 006 | m o d | ||
| 007 | cr cn |||||||| | ||
| 008 | 190102s2017 onca on 000 0 eng | ||
| 035 | |a (DNLM)BKSHLF:NBK534668 | ||
| 035 | |9 101740822 | ||
| 035 | |a 1740822 | ||
| 040 | |a DNLM |b eng |e rda |c DNLM |d UtOrBLW | ||
| 041 | 0 | 9 | |a eng |
| 042 | |a pcc | ||
| 043 | |a n-cn--- | ||
| 044 | |9 Canada | ||
| 060 | 0 | 0 | |a WE 550 |
| 130 | 0 | |a Clinical review report : AbobotulinumtoxinA (Dysport therapeutic) (November 2017) | |
| 245 | 1 | 0 | |a Clinical review report. |p AbobotulinumtoxinA (Dysport therapeutic) : |b (Ipsen Biopharmaceuticals Canada, Inc.). |
| 246 | 1 | |a AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.) | |
| 246 | 1 | |a Clinical review report for Dysport therapeutic uls | |
| 250 | |a Version 1.0. | ||
| 264 | 1 | |a Ottawa (ON) : |b Canadian Agency for Drugs and Technologies in Health, |c November 2017. | |
| 300 | |a 1 online resource (1 PDF file (123 pages)) : |b illustrations. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a CADTH common drug review | |
| 504 | |a Includes bibliographical references. | ||
| 520 | 3 | |a The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the treatment of upper limb spasticity (ULS) in adults. | |
| 536 | |a Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. | ||
| 588 | |a Description based on online resource; title from PDF title page (viewed March 8, 2019). | ||
| 650 | 1 | 2 | |a Muscle Spasticity |x drug therapy. |0 D009128Q000188 |
| 650 | 2 | 2 | |a Upper Extremity |x physiopathology. |0 D034941Q000503 |
| 650 | 2 | 2 | |a Botulinum Toxins, Type A |x therapeutic use. |0 D019274Q000627 |
| 650 | 2 | 2 | |a Botulinum Toxins, Type A |x adverse effects. |0 D019274Q000009 |
| 651 | 2 | |a Canada. |0 D002170 | |
| 655 | 2 | |a Systematic Review. |0 D000078182 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e issuing body. |0 n 2007182676 | |
| 830 | 0 | |a Common drug review clinical review report. |0 n 2014186107 | |
| 856 | 4 | 0 | |u http://www.ncbi.nlm.nih.gov/books/NBK534668/ |t 0 |
| 951 | |a 2436564 | ||
| 993 | |a CJM |b 20190212 | ||
| 998 | |a BKSHLF |b 20190102 | ||
| 998 | |a FER |b 20190102 | ||
| 999 | |a AUTH | ||
| 999 | f | f | |i 4b7171f5-c582-5bf5-82fb-816ea421fd7c |s e58291b0-958b-534a-bdc3-931c65b88ec5 |t 0 |
| 952 | f | f | |a Massachusetts College of Pharmacy and Health Sciences |b Online |c Online |d E-Collections |t 0 |e NCBI |h Other scheme |
| 856 | 4 | 0 | |t 0 |u https://www.ncbi.nlm.nih.gov/books/NBK534668/ |y Full text |
